Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure

AIDS Research and Human Retroviruses

Volumn 19, Issue 6, 2003, Pages 457-459

  González de Requena, Daniel ^a   Gallego, Oscar ^a   de Mendoza, Carmen ^a   Corral, Angélica ^a   Jiménez Nácher, Inmaculada ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; TREATMENT PLANNING; VIROLOGY;

EID: 0038391100     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203766774496     Document Type: Article

References (13)

1. Descamps D, Flandre P, Calvez V, et al.: Mechanism of virological failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege. JAMA 2000;283:205-211.
2. Markowitz M: Resistance, fitness, and potency. Mapping the paths to virological failure. JAMA 2000;283:250-251.
3. Austin D, Ferguson N, Fraser C, et al.: Understanding antiviral treatment failure: The role of pharmacokinetic/dynamycs and patient non-compliance in the emergence of resistance [abstract 212]. In: 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, October 1999.
4. Paris D, Ledergerber B, Weber R, et al.: Incidence and predictors of virological failure of antiretroviral triple drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999;15:1631-1638.
5. González de Requena D, Núñez M, de Mendoza C, Jiménez-Nácher I, and Soriano V: Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations. AIDS 2003;17:442-444.
6. Back D, Gatti G, Fletcher C, et al.: Therapeutic drug monitoring in HIV infection: Current status and future directions. AIDS 2002;16(Suppl 1):5-37.
7. Gallego O, de Mendoza C, Perez-Elias M, et al.: Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 2001;15:1701-1706.
8. Hugen P, Verweij-van Wissen C, Burger D, et al.: Simultaneous determination of the HIV protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B 1999;727:139-149.
9. Acosta E, Baken L, Page L, et al.: Indinavir concentrations and antiviral effect. Pharmacotherapy 1999;19:708-712.
10. Fletcher C, Anderson P, Nakuda T, et al.: Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;16:551-560.
11. Durant J, Clevenberg P, Garraffo R, et al.: Importance of protease inhibitors plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000;14:1333-1339.
12. Burger D, Hugen P, Droste J, et al.: Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive patients improves therapeutic outcomes after 1 year: Results from ATHENA [abstract 30]. In: 1st IAS Conference, Buenos Aires, Argentina, July 2001.
13. Barreiro P, Camino N, de Mendoza C, et al.: Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. Int J Antimicrob Agents 2002;20:438-443.